We have recently demonstrated the ability of a nanovaccine containing the Melan A Ag and α-GalCer and coated with anti-CLEC9A Abs to strongly induce the expansion of tumor Ag-specific CD8+ T cells from human PBMCs in vitro (12). Here, CLEC9A is linked to neoplasm.